A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Subjects

Trial Profile

A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs TD 1473 (Primary)
  • Indications Gastrointestinal disorders; Ulcerative colitis
  • Focus Adverse reactions; First in man
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 17 Feb 2017 Results published in a Theravance Biopharma media release.
    • 17 Feb 2017 According to a Theravance Biopharma media release, results from the study were presented the 12th Congress of the European Crohn's and Colitis Organization (ECCO).
    • 13 Feb 2017 According to a Theravance Biopharma media release, data from this trial will be presented at the 12th Congress of the European Crohn's and Colitis Organization (ECCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top